Tue, Jul 22, 2014, 10:39 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Geron Corporation (GERN) Message Board

lws2000 195 posts  |  Last Activity: 2 hours 37 minutes ago Member since: Nov 21, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Mayo knows what it is doing. The potential for telomere research and breakthroughs is almost infinite.

  • Imetelstat and Yale: New Combination Opportunities for Imetelstat

    Interesting:

    Yale School of Medicine and Yale Cancer Center researchers have uncovered a genetic vulnerability of cancer cells that express telomerase—an enzyme that drives their unchecked growth—and showed that telomerase-expressing cells depend upon a gene named p21 for their survival.

    Authors found that simultaneous inhibition of both telomerase and p21 inhibited tumor growth in mice. The telomerase enzyme is overexpressed in over 90% of human cancers, but not in normal cells, and expression of telomerase is necessary to initiate and promote cancer growth. In this study, the Yale team, led by first author Romi Gupta and corresponding author Narendra Wajapeyee of the Dept. of Pathology, showed how new pharmacological drug combinations can be applied to simultaneously target both telomerase and p21 to induce cell death in telomerase-expressing cancer cells.

    Finally, the authors also showed that their approach is also applicable for p53 mutant cancers if telomerase and p21 inhibition is combined with pharmacological restoration of p53 tumor suppressor activity. The study, which could open doors to novel therapies for telomerase inhibition, appears in the Proceedings of the National Academy of Sciences.

    Source: Yale Univ.

  • Reply to

    GERON MGMT MOVES TOO SLOWLY...

    by micaiah2004 Jul 21, 2014 7:07 PM
    lws2000 lws2000 Jul 21, 2014 9:14 PM Flag

    This is Mayo's game. Mayo took on the Imetelstat project with a certain level of exclusivity, since the outcome was highly speculative. Perhaps 1 in 20 of these drugs work out at all. The level of success here is rare. Mayo will dictate where and when this drug is used, at least for now. That is why Geron is so passive.

  • lws2000 lws2000 Jul 21, 2014 5:44 PM Flag

    Interesting:

    Yale School of Medicine and Yale Cancer Center researchers have uncovered a genetic vulnerability of cancer cells that express telomerase—an enzyme that drives their unchecked growth—and showed that telomerase-expressing cells depend upon a gene named p21 for their survival.

    Authors found that simultaneous inhibition of both telomerase and p21 inhibited tumor growth in mice. The telomerase enzyme is overexpressed in over 90% of human cancers, but not in normal cells, and expression of telomerase is necessary to initiate and promote cancer growth. In this study, the Yale team, led by first author Romi Gupta and corresponding author Narendra Wajapeyee of the Dept. of Pathology, showed how new pharmacological drug combinations can be applied to simultaneously target both telomerase and p21 to induce cell death in telomerase-expressing cancer cells.

    Finally, the authors also showed that their approach is also applicable for p53 mutant cancers if telomerase and p21 inhibition is combined with pharmacological restoration of p53 tumor suppressor activity. The study, which could open doors to novel therapies for telomerase inhibition, appears in the Proceedings of the National Academy of Sciences.

    Source: Yale Univ.

  • Reply to

    No Hidden Bad News About Imetelstat

    by lws2000 Jul 17, 2014 10:19 AM
    lws2000 lws2000 Jul 18, 2014 7:30 PM Flag

    I said, "Nothing is further from the truth, as Mayo (USA #1) continues full support". I have full confidence in Mayo (their data, patients and trials). As long as Mayo is upbeat, I will continue my long investment in Geron. Either there is something that we don't know that is devastating (don't think so), or as you say Imetelstat is likely a medical marvel. Actually, I am investing in Mayo Clinic's reputation. Geron is a bit mysterious, with some questionable history. Mayo, IMO, will keep Geron reasonably honest.

  • Reply to

    No Hidden Bad News About Imetelstat

    by lws2000 Jul 17, 2014 10:19 AM
    lws2000 lws2000 Jul 17, 2014 11:30 AM Flag

    Remissions & Cures with telomere control

  • The way Geron stock is acting one would think that announcements of Imelestat's failures are imminent. Nothing is further from the truth, as Mayo (USA #1) continues full support.

  • lws2000 lws2000 Jul 16, 2014 11:55 AM Flag

    My guess is that Geron will close over $3.00 on Monday.

  • Reply to

    This Was A Nice Beat

    by vincent90157 Jul 15, 2014 6:14 PM
    lws2000 lws2000 Jul 15, 2014 6:20 PM Flag

    Intel is back and will catch up in mobile in 2015. $50 by the end of the year.

    Sentiment: Strong Buy

  • lws2000 lws2000 Jul 15, 2014 3:37 PM Flag

    Yellen's remarks were not aimed at Geron (way underpriced), but pulled it down just the same. It may take a few days to get over $3.00. The trend is upward, but the road is bumping with "trolls" along the way. The Geron-Mayo marriage is in good shape.

  • lws2000 lws2000 Jul 15, 2014 2:22 PM Flag

    Jesus wanted equally and a fair-shake for the locals (money changers, etc.), and was anti-Roman (the occupying military force). This cost him his life on earth, but brought him immortality.

  • Geron is not over priced, but temporarily hit by Yellen's comments. Some small biotech companies and some social media companies are in bubble territory, according to Yellen. At this point in time, Geron is still in the $2.80 to $3.00 channel, as dictated by money managers. Mayo's good medicine and science will dominate soon (see Mayo's new brochure about Imetelstat). Stay with Geron, Mayo and breakthroughs around telomeres.

  • Reply to

    Exactly $3

    by micaiah2004 Jul 11, 2014 5:14 PM
    lws2000 lws2000 Jul 11, 2014 11:32 PM Flag

    This is amazing. Someone, somewhere can control the price of this stock to the penny with very powerful computers and very fast software. Mayo has created a "coiled spring" with an outstanding medicine (never seen before remissions tantamount to cures), in a phenomenal market environment (that has never been seen before). One day (soon I hope) the "coiled spring" will be released and surge forward. I hope someone will write a book :Miracle Drug and Market Forces. What is happening behind the scenes?

  • lws2000 lws2000 Jul 11, 2014 4:37 PM Flag

    The controlled channel is still with us ($2.80 to $3.20) as we closed @ $3.00 . The release of the Mayo hold moved us from the $2 channel to the $3 channel. Geron is a coiled spring that is about to be released. Mayo will see to that. The channel manipulation is about to end; we all sense that, even the shorts. Imetelstat is just too good to be held back much longer.

  • Reply to

    FDA hold was real suspect. Damage done however.

    by docaiii Jul 11, 2014 6:49 AM
    lws2000 lws2000 Jul 11, 2014 11:18 AM Flag

    I think we are saying the same thing. Mayo is the father, and Geron is the son. Mayo has the experience and wisdom, while Geron is still wet behind the ears, but learning.

  • Reply to

    FDA hold was real suspect. Damage done however.

    by docaiii Jul 11, 2014 6:49 AM
    lws2000 lws2000 Jul 11, 2014 10:55 AM Flag

    The hold now seems unnecessary. The fact that the Mayo hold has been lifted and the Geron hold has not, says something about the credibility, size, age, and stability of Mayo vs. Geron. Geron is barely a teenager trying to find its proper place in this world, while Mayo, the old sage, points to the road that needs to be traveled. The FDA is favoring Mayo, but Geron is not too far behind. Imetelstat is a gift to all (Mayo, Geron, researchers, patients).

  • lws2000 lws2000 Jul 8, 2014 8:04 PM Flag

    JUST REMEMBER: "Tantamount to a cure". This is a solid review, and it is all positive. The world is listening, and the FDA is listening. Nobody has any significant negatives (medicine & science).
    ***********************************************************
    FROM MAYO BROCHURE:

    At Mayo Clinic, discoveries happen every day. We focus on the needs of the patient, which require that our research model addresses patient-centered, patient-inspired discoveries.

    STOPPING HEMATOLOGICAL CANCER: New Drug Induces Remissions in Myelofibrosis

    The results of a Mayo Clinic study demonstrate that a drug named imetelstat induces remissions in some patients with myelofibrosis. This is a form of chronic leukemia that affects the patient’s bone marrow that is replaced by fibrosis (scar tissue) instead of blood-producing cells.

    Scientists do not yet know the exact mechanism of action for imetelstat, but believe it interferes with the survival and proliferation of cancer cells by inhibiting a critical enzyme called telomerase. One of the functions of telomerase is to repair the ends of chromosomes called telomeres, and because cancer cells have shorter than normal telomere size, they are particularly susceptible to the drug.

    The study results are promising. Some patients participating in the clinical trial taking imetelstat obtained dramatic responses, and we have seen some complete responses (tantamount to a cure), which is almost unheard of in this disease.

    Although patients may experience relief in response to other treatments, their bone marrow does not usually return to normal. But in the case of this new therapy, some of the patients participating in the trial developed normal bone marrow.

    Researchers studied imetelstat in 33 patients at Mayo Clinic and have now followed the first 22 patients for more than six months. Among these 22 patients, two achieved complete remissions and three partial remission, including reversal of bone marrow fibrosis in four of the five.

  • This is a contest for the ages, and a good subject for a PhD thesis. There are numerous subplots here. IMO, the "Miracle Drug" ultimately dominates, but the market control has been amazing. There seems to be something unusual going on, that is beyond normal market interactions. Mayo has told the whole world, loud and clear in their current brochure, that Imetelstat is the "real-thing". The FDA has to be listening, and has no reason to oppose Mayo's very carefully acquired results in their MF trials and studies.

  • lws2000 lws2000 Jul 8, 2014 1:54 PM Flag

    The Challenge has not been met. The Conclusion is that there is no public information that opposes the use of Imetelstat, and that the FDA is prepared to fully back it, with proper data gathering.

GERN
2.59-0.13(-4.78%)Jul 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Herbalife Ltd.
NYSETue, Jul 22, 2014 4:00 PM EDT
Puma Biotechnology, Inc.
NYSETue, Jul 22, 2014 4:01 PM EDT